Literature DB >> 3361431

Definitions and applications of mean transit and residence times in reference to the two-compartment mammillary plasma clearance model.

A N Kong1, W J Jusko.   

Abstract

The mean transit time (MTT) and the mean residence time (MRT) values of a linear two-compartment plasma clearance model were evaluated using definitions originally proposed by Rescigno and Gurpide. The MRT of the total body (MRTB) can be viewed as comprising the MRT in the central compartment (MRTC) and the MRT in the peripheral tissue compartment (MRTT). The MTT and MRT of each compartment can be envisioned as the average interval of time spent by a drug particle during a single passage and in all passages through it. Hence, the MRT is the product of MTT and the mean number of passages of a drug particle through the central (R + 1) or tissue (R) compartments. Physiologically, each MTT parameter is related to its apparent volume divided by all its clearance processes, reversible and irreversible (if any exist). Each MRT parameter is related to its apparent volume divided by only the sum of irreversible exit clearances. Applications of the five MTT/MRT parameters were made to disposition data for digoxin and gentamicin to assess their use as indicators of tissue persistency. This report provides additional physiological and pharmacokinetic insights into the disposition properties of drugs and reconciles various treatments of the two-compartment model using rate constants, volume/clearance terms, and transit/residence times.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3361431     DOI: 10.1002/jps.2600770213

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  12 in total

1.  Mean interconversion times and distribution rate parameters for drugs undergoing reversible metabolism.

Authors:  H Y Cheng; W J Jusko
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

2.  Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.

Authors:  Minjee Kim; Janice K Laramy; Gautham Gampa; Karen E Parrish; Richard Brundage; Jann N Sarkaria; William F Elmquist
Journal:  Drug Metab Dispos       Date:  2019-10-16       Impact factor: 3.922

Review 3.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

4.  Synthesis and biodistribution of Bowman-Birk soybean protease inhibitor conjugate with amphiphilic polyester.

Authors:  N I Larionova; I P Gladysheva; O V Polekhina; L P Kurochkina; E N Gorbatova
Journal:  Appl Biochem Biotechnol       Date:  1996 Oct-Nov       Impact factor: 2.926

5.  Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs.

Authors:  W F Elmquist; K K Chan; R J Sawchuk
Journal:  Pharm Res       Date:  1994-12       Impact factor: 4.200

6.  Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier.

Authors:  Janice K Laramy; Minjee Kim; Karen E Parrish; Jann N Sarkaria; William F Elmquist
Journal:  J Pharmacol Exp Ther       Date:  2018-02-12       Impact factor: 4.030

Review 7.  Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations.

Authors:  R E Kauffman; G L Kearns
Journal:  Clin Pharmacokinet       Date:  1992-07       Impact factor: 6.447

8.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

9.  Enhancement of tissue delivery and receptor occupancy of methylprednisolone in rats by a liposomal formulation.

Authors:  E V Mishina; R M Straubinger; N A Pyszczynski; W J Jusko
Journal:  Pharm Res       Date:  1993-10       Impact factor: 4.200

10.  Pharmacokinetics of factor IX in patients with haemophilia B. Methodological aspects and physiological interpretation.

Authors:  S Björkman; M Carlsson; E Berntorp
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.